UFM1 suppresses invasive activities of gastric cancer cells by attenuating the expression of PDK1 through PI3K/AKT signaling

Jian-Xian Lin, Xin-Sheng Xie, Xiong-Feng Weng, Sheng-Liang Qiu, Changhwan Yoon, Ning-Zi Lian, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Qi-Yue Chen, Long-Long Cao, Mi Lin, Ru-Hong Tu, Ying-Hong Yang, Chang-Ming Huang, Chao-Hui Zheng and Ping Li

Abstract

Background: UFM1 has been found to be involved in the regulation of tumor development. This study aims to clarify the role and potential molecular mechanisms of UFM1 in the invasion and metastasis of gastric cancer.

Methods: Expression of UFM1 in gastric tumor and paired adjacent noncancerous tissues from 437 patients was analyzed by Western blotting, immunohistochemistry, and real-time PCR. Its correlation with the clinicopathological characteristics and prognosis of gastric cancer patients was analyzed. The effects of UFM1 on the invasion and migration of gastric cancer cells were determined by the wound and trans-well assays, and the effect of UFM1 on subcutaneous tumor formation was verified in nude mice. The potential downstream targets of UFM1 and related molecular mechanisms were clarified by the human protein kinase assay and co-immunoprecipitation technique.

Results: Compared with the corresponding adjacent tissues, the transcription level and protein expression level of UFM1 in gastric cancer tissues were significantly downregulated \( P < 0.05 \). The 5-year survival rate of gastric cancer patients with low UFM1 expression was significantly lower than the patients with high UFM1 expression \( (42.1\% \text{ vs } 63.0\%, \ P < 0.05) \). The invasion and migration abilities of gastric cancer cells with stable UFM1 overexpression were significantly decreased, and the gastric cancer cells with UFM1 stable knockdown showed the opposite results; similar results were also obtained in the nude mouse model. Further studies have revealed that UFM1 could increase the ubiquitination level of PDK1 and decrease the expression of PDK1 at the protein level, thereby inhibiting the phosphorylation level of AKT at Ser473. Additionally, the effect of UFM1 on gastric cancer cell function is dependent on the expression of PDK1. The expression level of UFM1 can improve the poor prognosis of PDK1 in patients with gastric cancer.

Conclusion: UFM1 suppresses the invasion and metastasis of gastric cancer by increasing the ubiquitination of PDK1 through negatively regulating PI3K/AKT signaling.

Keywords: UFM1, PDK1, Gastric cancer, EMT
Background
Gastric cancer is a malignant tumor with a high incidence and mortality. Currently, the overall therapeutic effect of gastric cancer treatment is not satisfactory, and the 5-year survival rate is still low [1, 2]. Recurrence and metastasis of gastric cancer is the main cause of death and also a complex pathological process caused by a series of molecular changes, while the clinical treatment of recurrence and metastasis is still not satisfactory [3]. Therefore, the study of key molecular events and signaling pathways in the development and metastasis of gastric cancer is helpful for revealing the mechanism of gastric carcinogenesis, development and improving the diagnosis of early gastric cancer, even providing great significance for the treatment of advanced gastric cancer.

UFM1 is a small molecule ubiquitin protein that was first discovered by Komatsu et al. in 2004 [4]. It consists of 85 amino acids, has a modification function similar to that of ubiquitin, which is covalently bound to other proteins such as ubiquitin molecules. This phenomenon is called UFM1 ufmylation [5]. UFM1 and its modification system are widely and conservatively presented in animals and plants, especially in cells that secrete proteins, which are mainly distributed in the cytoplasm and nucleus [6]. At present, UFM1 and its modification system are involved in a variety of pathophysiological processes, and participate in biological processes such as the cell cycle, cell survival, hypoxia tolerance, and fatty acid β oxidation [7–9]. UFM1 usually exists as the precursor form inside cells. For UFM1 to play its role in attaching to the target protein, it must be digested to expose the glycine at the carboxy terminus, followed by a series of enzyme cascades [10]. The enzyme cascades of the UFM1 system include the initial activation of the treated UFM1 by UBA5, followed by transfer to UFC1 and then to UFL1. UFL1 recognizes the target protein and helps UFM1 bind to the target protein. Finally, UFM1 processes the target protein to attain its important biological function [11]. As an important transduction molecule of PI3K signaling pathway, the binding of PDK1 to PI3P plays an important role in the activation of AKT and other kinases. It regulates a large number of AGC protein kinase family members to control cellular responses and in physiological processes such as cell growth, proliferation and survival. GSK3β is an important target molecule downstream of AKT. It is generally believed that GSK3β is a tumor suppressor, and the activity of tumor cells is related to the inhibition of GSK3β, and is also a downstream molecule of PI3K/AKT pathway.

Recently, Xi et al. have shown that UFM1 can inhibit the sensitivity of endothelial cells to LPS through the NF-κB signaling pathway [12]. UFM1 is currently known to be closely related to several human diseases, including tumors. Although UFM1 has been reported to be involved in the progression of breast cancer, its role in gastric cancer is still unclear [13]. Our previous study has shown that the expression level of UFM1 is significantly down regulated in gastric cancer tissues than in adjacent tissues. Further analysis revealed a low expression level of UFM1 in gastric cancer, which was positively correlated with the TNM staging and poor prognosis of patients, suggesting that UFM1 may be a potential tumor suppressor gene in gastric cancer. We further studied the effects of UFM1 on gastric cancer function and in-depth mechanisms through a series of in vitro and in vivo experiments, aiming to clarify the relationship between UFM1 and the development of gastric cancer, and provide a new theoretical basis for early intervention and potential targeted treatment of gastric cancer.

Materials and methods
Human tissues
Gastric cancer specimens and the respective adjacent non-tumor tissues (within a minimum distance of 5 cm from the excised tumor) of 236 patients were obtained from the Department of Gastric Surgery, Fujian Medical University Union Hospital with detailed clinicopathologic parameters and detailed follow-up information from January 2013 to January 2018. All patients with gastric cancer had not received adjuvant chemotherapy before surgery and underwent gastrectomy with D2 lymph node (LN) dissection. Clinicopathological characteristics included age, gender, tumor size, tumor location, differentiation, histological type, depth of invasion, LN metastasis, distant metastasis, and TNM stage. T stage, N stage, and TNM stage were determined by using the 8th edition of the AJCC staging system [14]. Collected tissue samples were immediately frozen in liquid nitrogen and stored at −80 °C until further analysis. Among them, samples from 116 patients (collected by gastrectomy from 2017 to 2018) were subjected to Western blotting and RT-qPCR analysis. Samples from the other 120 patients (collected by gastrectomy in 2013 to 2014) were collected for immunohistochemical staining. This study was approved by the ethics committee of Fujian Medical University Union Hospital, and written consent was obtained from all involved patients.

Follow-up
All patients were followed up every 3 months for the first 2 years and every 6 months for the next 3–5 years. The last follow-up time point was January 2018. Routine examinations of follow-up, including a physical examination, laboratory tests (CA19–9, CEA and CA72–4),
chest X-ray, abdominal CT, B ultrasound, and gastroscopy were performed each year. Overall survival was defined as the time from surgery to the date of death or to the last follow-up date, or to expiration of the follow-up (e.g., lost to follow-up, death from other diseases, etc.). The median follow-up interval was 37 months (range 0–62 months).

**Immunohistochemistry (IHC) and immunofluorescence**

Immunohistochemistry (IHC) and immunofluorescence assays have been described previously [15]. Detailed methods are available in the Additional file 1.

**Cell culture and transfection**

Human gastric cancer cell lines (N87, AGS, MGC-803 and HGC-27 cells) were purchased from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). Cells were cultured at 37 °C in a humidified atmosphere of 5% CO2 in 1640 (Gibco, Grand Island, NY) or DMEM/F12 1:1 medium containing 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY).

Lentiviral constructs of UFM1 (NM_016617.4), shRNA (shUFM1), UFM1 overexpression (UFM1), and their corresponding empty vectors Lenti-scramble and Lentieempty (shNCUFM1 and NCUFM1) were purchased from Shanghai Genechem Co. Ltd., China. The siRNA of PDK1 was purchased from Cell Signaling Technology (Danvers, MA); UFM1 (ab109305), β-catenin (ab6302), GAPDH (ab8245), N-cadherin (ab18203), E-cadherin (ab1416), Vimentin (#92547), PI3Kp110 and PI3Kp85 (ab127617) were from Abcam (Cambridge, UK). Detailed methods are available in the Additional file 1.

**Western blot assay**

Samples and cells were collected for Western blotting as previously described [17]. Western blot analysis was performed using the following antibodies: PDK1 (#13037), Snail (#3879), p-AKT (#4060), AKT (#4685), GSK3β (#12456) and pGSK3β (#5558) were purchased from Cell Signaling Technology (Danvers, MA); UFM1 (ab109305), β-catenin (ab6302), GAPDH (ab8245), N-cadherin (ab18203), E-cadherin (ab1416), Vimentin (#92547), PI3Kp110 and PI3Kp85 (ab127617) were from Abcam (Cambridge, UK). Detailed methods are available in the Additional file 1.

**Human Phospho-kinase Array**

The relative levels of protein phosphorylation were tested using the Human Phospho-Kinase Array Kit (ARY003B, R&D Systems, Inc. USA & Canada) according to the manufacturer’s protocol. An equal amount of protein (600 mg) was extracted from stable cells (shNCUFM1 AGS and shUFM1 AGS) and used to compare the kinase activity of UFM1 with and without UFM1 knockdown.

**Immunoprecipitation and in vitro ubiquitination assay**

Cells were washed with ice-cold PBS and lysed using IP pyrolysis solution containing a proteinase inhibitor cocktail tablet (Roche; 1 mM PMSF; 2 mM nethylmaleimide), using a pestle for homogenization. Lysates were incubated on ice for 30 min before cellular debris and nuclei were removed by centrifugation at 12,000 g for 15 min. Cell lysates were incubated with the corresponding primary antibody (PDK1 or UFM1) overnight at 4 °C. Protein A–Sepharose (Amersham Biosciences, Piscataway, NJ) beads in a 50:50 mixture of 50 mmol/L Tris buffer, pH 7.0 were added and further incubated for another 4 h at 4 °C. After elution, the proteins were separated by SDS-PAGE followed by Western blot analysis using the corresponding antibody. For the in vivo ubiquitination assay, the cell lysate (an equal amount of protein
extracted from stable cells for the ubiquitination analysis) extracted from UFM1 knockdown or overexpression AGS cells was immunoprecipitated with anti-PDK1 antibody, and the ubiquitination level of PDK1 was tested with an anti-Ub antibody.

**Tumor xenograft transplantation assay**

Male BALB/c nude mice (age, 4–5 weeks; weight, 14–16 g; Institute of Zoology, Chinese Academy of Sciences) were randomly divided into two groups: Negative control (NC) and UFM1 overexpression groups (n = 5/group). All animal procedures were performed according to the Animal Protection Committee of Fujian Medical University (Fuzhou, China), and the animal study was approved by the Ethics Committee of Fujian Medical University/Laboratory Animal Center (Fuzhou, China). The permission number is FJMUIACUC, 2019–0014. Part of the mice were primed with an injection of 1 × 10^7 stable HGC-27 cells in 100 μl of phosphate-buffered saline (PBS) into the right axillary fossa of nude mice. The tumor volume was measured every 7 days and evaluated as follows: (length×width^2)/2 cm^3. The mice were sacrificed (cervical dislocation) on day 35 after injection, and the tumor weight was measured. The xenograft tumors were fixed and embedded in paraffin, followed by HE (Hematoxylin-eosin) staining.

**Metastasis experiment in nude mice**

The other 10 BALB/c mice were randomly divided into two groups: Negative control (NC) and UFM1 overexpression groups (n = 5/group), mice were anesthetized by intraperitoneal injection of 1% sodium pentobarbital (40 mg/kg). In the middle of the dorsal aspect, the midline of the left iliac crest and the posterior tibial line, an incision of about 1.5 cm was taken into the abdomen to the more advanced TNM stage (Table 1). Survival analysis was performed using the Kaplan-Meier method, and the curves were compared using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model to further evaluate all the significant prognostic factors that were found in the univariate analysis. The difference was considered statistically significant at P < 0.05.

**Results**

**UFM1 is downregulated in gastric cancer**

By qPCR analysis, we found that the transcription level of UFM1 was downregulated in gastric cancer tissues (n = 93, 80.2%) compared with the corresponding adjacent tissues (Fig. 1a). Using Western blot analysis, we confirmed that protein expression levels of UFM1 were significantly lower (n = 44, 41.9%) in tumor tissues compared with the corresponding adjacent nontumor tissues (n = 61, 58.1%, Fig. 1b, c) among 105 gastric cancer patients. In addition, we analyzed (Data mining from the published Oncomine database) the mRNA levels of UFM1 between normal and cancerous gastric tissue. The results showed that the transcription level of UFM1 in gastric cancer tissues was downregulated based on the data uploaded by Wang, consistent with the results of our present study (Additional file 3: Figure S1A).

In addition, we used immunohistochemistry to detect the expression of UFM1 in 120 paraffin-embedded tissues of gastric cancer (Fig. 1d, Additional file 3: Figure S1B) and then analyzed the effect of its expression on the prognosis of gastric cancer patients. The results showed that the expression of UFM1 was significantly higher in adjacent tissues than in the corresponding gastric cancer tissues (Fig. 1e). Among the 120 patients with primary gastric cancer, the UFM1 score was low in 91 cases (75.8%) and high in only 26 cases (24.2%), and the downregulation of UFM1 expression was closely related to the more advanced TNM stage (Table 1). Survival analysis showed that the 5-year survival rate of low UFM1 expression was 42.1%, which was significantly lower than the high UFM1 expression (P < 0.05, Fig. 1f). Additionally, we analyzed the effect of the UFM1 expression on the prognosis of gastric cancer patients according to the TCGA database [18]. The results also showed that patients with gastric cancer with high expression of UFM1 had a better prognosis (Additional file 3: Figure S1C). Concurrently, we also detected the expression level of UFM1 in several gastric cancer cell lines and found that the expression level of UFM1 was negatively correlated with the differentiation degree of gastric cancer cell lines (N87 is a highly differentiated gastric cancer cell, AGS and MGC-803 are moderately differentiated, HGC-27 is poorly differentiated) (Fig. 1g), suggesting that UFM1 may be closely related to the progression of gastric cancer.

**Statistical analysis**

All the data were processed using the SPSS23.0 statistical software package and Prism 7.0 software (GraphPad). Continuous values are expressed as the mean ± standard deviation and analyzed using the Student’s t-test. Categorical variables were analyzed using the χ² or Fisher’s exact tests. Univariate survival analysis was performed using the Kaplan-Meier method, and the curves were compared using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model to further evaluate all the significant prognostic factors that were found in the univariate analysis. The difference was considered statistically significant at P < 0.05.
UFM1 suppresses the invasion and metastasis of gastric Cancer cells

To investigate the potential role of UFM1 in the invasion and metastasis of gastric cancer, we constructed HGC-27 and AGS gastric cancer cell lines with stable overexpressing or downregulation of UFM1 (Additional file 4: Figure S2A). We found that knockdown of UFM1 expression promoted the migration and invasion ability of
these two cells in vitro (Fig. 2a, b, c); in contrast, upregulated UFM1 expression levels resulted in cell wound healing inhibition (Fig. 2d), as well as a significant reduction of the migration and invasion ability (Fig. 2e, f).

We also constructed a subcutaneous tumor model in nude mice to evaluate the effect of UFM1 on the tumorigenic ability of gastric cancer cells in vivo. After overexpression of UFM1, tumor growth was inhibited, and the growth of tumor volume was significantly decelerated compared with the control group (Additional file 4: Figure S2B). Moreover, the tumors were completely excised together with the skin, HE staining revealed that the tumor had significantly invaded the surrounding tissues in the control group, and the boundary with the surrounding tissues was unclear; however, when UFM1 was overexpressed, the boundary between the tumor and the surrounding tissue was clearly visible (Fig. 2g). In addition, we also performed a nude mouse liver metastasis model experiment. Stable HGC-27 cells which overexpression UFM1 was injected into the spleen of 8-week-old nude mice. Tumor burden was assessed at 16 weeks of age. Macroscopic examination, the representative images of whole livers showing reduction in UFM1 liver tumor burden after infection with UFM1 compared to infection with control (Fig. 2h). These results indicate that UFM1 not only inhibits the tumorigenic ability of

Table 1 Relationships between UFM1 protein expressions in gastric cancer tissues and various clinicopathological variables

| Variables                        | Total | UFM1 expression | P    |
|----------------------------------|-------|-----------------|------|
|                                 |       | Low 91          | High 29 |
| Gender                           |       |                 |      |
| Male                             | 95    | 70              | 25   |
| Female                           | 25    | 21              | 4    |
| Age at surgery (years)           |       |                 |      |
| >60                              | 80    | 63              | 17   |
| ≤60                              | 40    | 28              | 12   |
| Size of primary tumor (cm)       |       |                 |      |
| >5                               | 48    | 35              | 13   |
| ≤5                               | 72    | 56              | 16   |
| Location of primary tumor        |       |                 |      |
| Lower 1/3                        | 46    | 33              | 13   |
| Middle 1/3                       | 19    | 16              | 3    |
| Upper 1/3                        | 42    | 31              | 10   |
| More than 1/3                    | 14    | 11              | 3    |
| Degree of differentiation        |       |                 |      |
| Well/moderate                    | 47    | 35              | 12   |
| Poor and not                     | 83    | 56              | 17   |
| Histological type                |       |                 |      |
| Papillary                        | 54    | 43              | 11   |
| Tubular                          | 47    | 23              | 14   |
| Mucinous                         | 9     | 8               | 1    |
| Signet-ring cell                 | 20    | 17              | 3    |
| Depth of invasion                |       |                 |      |
| T1+ T2                           | 17    | 10              | 7    |
| T3+ T4                           | 103   | 81              | 22   |
| Lymph node metastasis            |       |                 |      |
| N0                               | 14    | 9               | 5    |
| N1–3                             | 106   | 82              | 24   |
| TNM stage                        |       |                 |      |
| I + II                           | 38    | 24              | 14   |
| III + IV                         | 83    | 67              | 15   |
| Distant metastasis               |       |                 |      |
| Negative                         | 115   | 87              | 28   |
| Positive                         | 5     | 4               | 1    |
Fig. 2 The expression of UFM1 was negatively correlated with the aggressive behaviors of gastric cancer cells in vitro and in vivo. 

- **a** Wound-healing assays of stably down-regulated UFM1 expression in HGC-27 and AGS cells were performed. The representative images and the quantification were presented (*P < 0.05).
- **b** Migration assays of stably down-regulated UFM1 expression in HGC-27 and AGS cells were performed. The representative images and the quantification of the results are presented as mean ± SD; scale bar, 50 μm (*P < 0.05).
- **c** Invasion assays of stably down-regulated UFM1 expression in HGC-27 and AGS cells were performed. The representative images and the quantification of the results are presented as mean ± SD; scale bar, 50 μm (*P < 0.05).
- **d** Wound-healing assays of stably up-regulated UFM1 expression in HGC-27 and AGS cells were performed. The representative images and the quantification was presented (*P < 0.05).
- **e** Migration assays of stably up-regulated UFM1 expression in HGC-27 and AGS cells were performed. The representative images and the quantification of the results are presented as mean ± SD; scale bar, 50 μm (*P < 0.05).
- **f** Invasion assays of stably up-regulated UFM1 expression in HGC-27 and AGS cells were performed. The representative images and the quantification of the results are presented as mean ± SD; scale bar, 50 μm (*P < 0.05).
- **g** Gross photos of flank xenografts and microscopic photo leading edge of tumors.
- **h** Representative images of whole livers showing reduction in UFM1 liver tumor burden after infection with UFM1 compared to infection with control and showing a significant reduction in tumor burden after infection with UFM1 compared to control (n = 5 mice). **P < 0.01**, two-sided unpaired t-test. Data are mean ± SD.
gastric cancer cells but also significantly reduces the invasion ability of gastric cancer cells.

**UFM1 inhibits the invasion and metastasis of gastric Cancer through EMT**

Epithelial mesenchymal transition (EMT) makes cancer cells invasive and metastatic, and it plays a key role in tumor progression. We observed that knockdown of UFM1 resulted in a decrease in tight junctions between cells and a morphological change in epithelial mesenchymal transition in gastric cancer cells (Fig. 3a, b). We further examined the potential effect of UFM1 on EMT-related marker molecules. Western blot showed that E-cadherin expression was decreased and of N-cadherin, Vimentin, and Snail were increased in gastric cancer cells, which downregulated UFM1 expression (Fig. 3c). In contrast, overexpression of UFM1 had an opposite effect on the related proteins (Fig. 3d). These results were also confirmed at the transcriptional level (Fig. 3e). Furthermore, we used immunofluorescence to detect the expression levels of E-cadherin and N-cadherin in AGS cells with stable overexpression and knockdown of UFM1 (Fig. 3f).

![Fig. 3](image-url)
UFM1, the results also consistent with the findings obtained by Western blot (Fig. 3f).

**UFM1 suppresses epithelial-to-mesenchymal transition of gastric cancer by inactivating the PI3K/AKT pathway**

To explore the mechanism of UFM1 on the invasion and metastasis of gastric cancer, we screened 10 differentially regulated signaling molecules in AGS (downregulated UFM1 expression levels) using the human phosphokinase microarray. We found that the levels of p-AKT (S473) and p-AKT (T308) were significantly increased (Fig. 4a, Additional file 5: Figure S3A). Next, we detect the expression levels of PI3K/AKT/GSK3β-related proteins in AGS and HGC-27 cells stably transfected with UFM1. Overexpression of UFM1 inhibited the phosphorylation of AKT and GSK3β. Phosphorylation of AKT and GSK3β increased following the downregulation of UFM1 expression, but there was no significant difference in protein levels between P110 and P85 (Fig. 4b). This result indicates that UFM1 can affect the PI3K/AKT signaling pathway by affecting the phosphorylation of AKT. Subsequently, we used the PI3K inhibitor LY294002 to assess whether it could inhibit the invasion phenotype of gastric cancer (Additional file 5: Figure S3B). Further studies showed that LY294002 significantly inhibited the phosphorylation of AKT, but the expression level of UFM1 did not significantly change. However, the phosphorylation level of AKT was significantly increased after knocking down UFM1 (Additional file 5: Figure S3C). Therefore, we propose that UFM1 functions upstream of AKT. In addition, we also found that LY294002 blocked the effect of cell (stable transfection of UFM1) migration (Fig. 4c, d) and the phosphorylated AKT/GSK3β and EMT-related protein levels (Fig. 4e). Based on the above findings, we believe that UFM1 affects the phosphorylation level of AKT/GSK3β and EMT in gastric cancer cells, but it does not affect PI3K.

**UFM1 suppresses the metastatic potential and EMT of gastric cancer in a PDK1-dependent manner**

To further explore the possible mechanism by which UFM1 regulates the metastatic potential and EMT in gastric cancer, we used co-immunoprecipitation to identify possible binding proteins for UFM1. The results showed that UFM1 binds to PDK1 but not to E-cadherin, N-cadherin, PI3K, AKT or Snail (Fig. 5a, Additional file 6: Figure S4A). To further investigate the effect of UFM1 on PDK1 expression, we also searched the TCGA database and found no significant correlation between UFM1 and PDK1 at the transcriptional level [19] (Additional file 6: Figure S4B). Therefore, we hypothesized that UFM1 might regulate the protein level of PDK1 through post-translational modification. It has been reported in the literature that PDK1 contains a polyubiquitination modification [20]. Consequently, we examined the ubiquitination level of PDK1 after overexpression and knockdown of UFM1. When the expression level of UFM1 was decreased, the ubiquitination levels of PDK1 were decreased and the protein levels of PDK1 were elevated. Conversely, after overexpression of UFM1, the PDK1 ubiquitination level was elevated and protein levels reduced (Fig. 5b). Using the Genemania website, we also found that the UFM1 modification system interacts with PDK1 (Additional file 6: Figure S4C), further validating our results [21]. Correspondingly, as the expression level of UFM1 gradually increased, the expression level of PDK1 decreased (Additional file 6: Figure S4D). In addition, our immunofluorescence results were consistent with the findings of the Western blot analysis (Fig. 5c).

We then investigated whether PDK1 could play a key role in UFM1-mediated gastric cancer metastasis inhibition. In AGS cells, we used PDK1 siRNA and observed a significant reduction of cell invasiveness (Additional file 6: Figure S4E). Furthermore, Western blot analysis showed that PDK1 siRNA could inhibit the downregulation of E-cadherin and the expression of N-cadherin and vimentin mediated by UFM1 in AGS (downregulated UFM1 expression) (Fig. 5d). In the trans-well assay, PDK1 siRNA blocked cell metastasis, which was inhibited by UFM1 (Fig. 5e, f). Subsequently, the related protein expression levels (proteins were extracted from subcutaneous tumor tissues) of the UFM1 overexpression group was consistent with the conclusions obtained from cell experiments (Additional file 6: Figure S4F). These results suggest that UFM1 inhibits cell migration, invasion and EMT in gastric cancer, and these phenomena are PDK1-dependent.

**Low expression of UFM1 and high expression of PDK1 indicate a poor prognosis in patients with gastric Cancer**

In addition, we examined the protein level of PDK1 in paraffin-embedded tissue samples from 120 patients with gastric cancer (Additional file 7: Figure S5). The score for PDK1 was higher in gastric cancer tissues (n = 55, 45.8%) than the corresponding adjacent tissues (Fig. 6a, b). The survival analysis showed that patients with high expression of PDK1 had worse survival rates than those with low expression of PDK1 (64.3% vs. 82.3%, p = 0.014, Fig. 6c). Combined with the co-expression of UFM1 and PDK1, we found that patients with low expression of UFM1 and high expression of PDK1 had the worst prognosis (58.4%), while those with high expression of UFM1 and low expression of PDK1
had the best prognosis (Fig. 6d). We used a Cox proportional hazards regression model to analyze the effects of UFM1 and PDK1 expression and other clinicopathological data on the prognosis of patients with gastric cancer. Univariate analysis showed that depth of invasion, lymph node metastasis, TNM stage, distant metastasis, UFM1 expression, PDK1 expression, and combined with UFM1 and PDK1 expression were closely related to patient prognosis (Table 2). Multivariate Cox regression analysis showed that co-expression of UFM1 and PDK1 and TNM stage were both independent predictors for gastric cancer (Table 3).

**Discussion**

Previous studies of UFM1 have focused on the pathophysiological effects of the endoplasmic reticulum stress response. However, whether UFM1 is expressed in epithelial cells and its biological function are still unclear. In the present study, we found that UFM1 was downregulated in gastric cancer tissue. Gastric cancer patients...
with low expression of UFM1 presented a poor prognosis. UFM1 had an inhibitory effect on the tumorigenicity, invasion and migration of gastric cancer cells. Further studies have shown that UFM1 can inhibit the phosphorylation of AKT and downstream GSK3β by binding to PDK1 and increasing its ubiquitination, thereby inhibiting EMT of gastric cancer cells and exerting a tumor suppressor function.

EMT is an important biological process for the invasion and metastasis of epithelial-derived malignant tumor cells. It plays a key role in tumor invasion and metastasis, and it is an important step in the malignant...
progression of tumors [22, 23]. Changes in the cytoskeleton and related phenotypic genes are often associated with the development of EMT in epithelial tumor cells, such as a decrease in the epithelial marker E-cadherin and the interstitial marker N-cadherin, an increase in Vimentin or other protein involved in tight junctions, loss of polarity and morphological changes of mesenchymal cells, which result in decreased adhesion of tumor

**Fig. 6** Effect of UFM1 and PDK1 on prognosis of patients with gastric cancer. 

- **A** The expression of PDK1 protein in gastric tumor tissues and respective adjacent tissues were analyzed using IHC, magnification, × 100 and × 400.
- **B** PDK1 expression scores are shown as box plots. The expression of PDK1 in gastric tumor tissues and respective adjacent tissues was compared using the t-test. **n** = 120 (*, P < 0.005).
- **C** Kaplan-Meier survival curve of gastric cancer patients with “High PDK1” or “Low PDK1” (P < 0.05, log-rank test).
- **D** Kaplan-Meier analysis of the correlation between the combined expression of UFM1 and PDK1 with the overall survival of gastric cancer patients (P < 0.05, log-rank test).
- **E** Working model of the role of UFM1 in PDK1 signaling and gastric cancer cell invasion
cells and an enhanced exercise capacity [24]. EMT activation is dependent on the stimulation of a variety of extracellular signals and the driving of EMT-inducible transcription factors such as Snail, ZEB, and Twist, which transform epithelial cells into a mesenchymal phenotype with migration and invasion abilities [25]. Multiple signaling pathways have been found to be involved in EMT, including the TGF-β/Smad, Wnt, Notch, ERK/MAPK, PI3K/AKT/GSK3β and NF-κB signaling pathways [25–27]. In this study, we found that UFM1 activated GSK3β by inhibiting the AKT/GSK3β pathway to regulate EMT. Interestingly, when we upregulated and downregulated the expression level of UFM1, there was no significant difference in protein levels between P110 and P85. Therefore, we considered that UFM1 does not affect the phosphorylation level of AKT/GSK3β by affecting PI3K. By using immunoprecipitation, we found that UFM1 and PDK1 could bind to each other. When UFM1 was overexpressed, the expression level of PDK1 was decreased, and when the opposite UFM1 was weakened, the expression level of PDK1 was increased. The PDK1 molecule contains 36 lysines, 27 of which are located in the N-terminal kinase domain and 9 of which are located in the C-terminal platelet-leukocyte C kinase substrate homolog domain (C-terminal pleckstrin homology domain) [28, 29]. PDK1 belongs to the AGC protein kinase family (cAMP and cGMP-dependent protein kinase C), which phosphorylates many downstream proteins such as AKT, p90RSK, p70S6K, SGK and PKC [28, 30–32]. Studies have shown that blocking the interaction between PDK1 and AKT can inhibit the growth and metastasis of melanoma [33]. Therefore, we used siRNA to knockdown PDK1 in AGS cells with stable downregulated expression of UFM1. In our study, we thought that using the same cell line for overexpression and knockdown of the target gene for cell function assay could avoid the interference of cell line changes on the experimental results, and it can also reflect the effect of genetic changes on the function of the cell line. We found that also in many literatures also overexpressed and knocked out using the same cell line [34, 35]. We tested the expression level of UFM1 protein in different gastric cancer cell lines and found that AGS was at a medium level. Therefore, we mainly chose AGS for overexpression and knockdown then for cell function experiments. In addition, we verified these results in HGC-27 gastric cancer cells. Although the expression level of CDK5RAP3 in HGC-27 was low, but the experiment after knocking down and overexpression the target gene also reflects the effect of the gene on cell function. Furthermore, we found that the inhibitory effect of UFM1 on gastric cancer cell EMT was also prevented when PDK1 was knocked down. Studies by Paolo Armando et al. have shown that PDK1 deletion can affect the EMT process in endothelial cells and an enhanced exercise capacity [24]. EMT activation is dependent on the stimulation of a variety of extracellular signals and the driving of EMT-inducible transcription factors such as Snail, ZEB, and Twist, which transform epithelial cells into a mesenchymal phenotype with migration and invasion abilities [25]. Multiple signaling pathways have been found to be involved in EMT, including the TGF-β/Smad, Wnt, Notch, ERK/MAPK, PI3K/AKT/GSK3β and NF-κB signaling pathways [25–27]. In this study, we found that UFM1 activated GSK3β by inhibiting the AKT/GSK3β pathway to regulate EMT. Interestingly, when we upregulated and downregulated the expression level of UFM1, there was no significant difference in protein levels between P110 and P85. Therefore, we considered that UFM1 does not affect the phosphorylation level of AKT/GSK3β by affecting PI3K. By using immunoprecipitation, we found that UFM1 and PDK1 could bind to each other. When UFM1 was overexpressed, the expression level of PDK1 was decreased, and when the opposite UFM1 was weakened, the expression level of PDK1 was increased. The PDK1 molecule contains 36 lysines, 27 of which are located in the N-terminal kinase domain and 9 of which are located in the C-terminal platelet-leukocyte C kinase substrate homolog domain (C-terminal pleckstrin homology domain) [28, 29]. PDK1 belongs to the AGC protein kinase family (cAMP and cGMP-dependent protein kinase C), which phosphorylates many downstream proteins such as AKT, p90RSK, p70S6K, SGK and PKC [28, 30–32]. Studies have shown that blocking the interaction between PDK1 and AKT can inhibit the growth and metastasis of melanoma [33]. Therefore, we used siRNA to knockdown PDK1 in AGS cells with stable downregulated expression of UFM1. In our study, we thought that using the same cell line for overexpression and knockdown of the target gene for cell function assay could avoid the interference of cell line changes on the experimental results, and it can also reflect the effect of genetic changes on the function of the cell line. We found that also in many literatures also overexpressed and knocked out using the same cell line [34, 35]. We tested the expression level of UFM1 protein in different gastric cancer cell lines and found that AGS was at a medium level. Therefore, we mainly chose AGS for overexpression and knockdown then for cell function experiments. In addition, we verified these results in HGC-27 gastric cancer cells. Although the expression level of CDK5RAP3 in HGC-27 was low, but the experiment after knocking down and overexpression the target gene also reflects the effect of the gene on cell function. Furthermore, we found that the inhibitory effect of UFM1 on gastric cancer cell EMT was also prevented when PDK1 was knocked down. Studies by Paolo Armando et al. have shown that PDK1 deletion can affect the EMT process in endothelial cells and an enhanced exercise capacity [24].

### Table 2 Univariate analysis of the correlation between clinicopathological parameters and survival of patients with gastric cancer

| Clinicopathological parameters | Three-year cumulative survival rate | Log-Rank Test | p   |
|-------------------------------|------------------------------------|--------------|-----|
| Gender                        |                                    |              |     |
| Male                          | 72.7                               | 0.096        | 0.756|
| Female                        | 80.0                               |              |     |
| Age (years)                   |                                    |              |     |
| > 60                          | 75.6                               | 0.102        | 0.749|
| ≤ 60                          | 70.5                               |              |     |
| Tumor size (cm)               |                                    |              |     |
| > 5                           | 69.9                               | 1.435        | 0.231|
| ≤ 5                           | 76.8                               |              |     |
| Location of tumor             |                                    |              |     |
| Lower 1/3                     | 73.3                               | 3.943        | 0.268|
| Middle 1/3                    | 82.6                               |              |     |
| Upper 1/3                     | 66.8                               |              |     |
| More than 1/3                 | 92.9                               |              |     |
| Degree of differentiation     |                                    |              |     |
| Well/moderate                 | 78.7                               | 0.332        | 0.564|
| Poor and not                  | 70.8                               |              |     |
| Histological type             |                                    |              |     |
| Papillary                     | 65.4                               | 3.825        | 0.281|
| Tubular                       | 83.6                               |              |     |
| Mucinous                      | 66.7                               |              |     |
| Signet-ring cell              | 85.0                               |              |     |
| Depth of invasion             |                                    |              |     |
| T1 + T2                       | 100.0                              | 5.357        | 0.021|
| T3 + T4                       | 70.1                               |              |     |
| Lymph node metastasis         |                                    |              |     |
| Negative                      | 100.0                              | 4.453        | 0.035|
| Positive                      | 70.7                               |              |     |
| TNM stage                     |                                    |              |     |
| I + II                        | 97.4                               | 12.542       | 0.000|
| III + IV                      | 63.2                               |              |     |
| Distant metastasis            |                                    |              |     |
| Negative                      | 75.9                               | 6.798        | 0.009|
| Positive                      | 40.0                               |              |     |
| UFM1 expression               |                                    |              |     |
| Low                           | 69.1                               | 4.946        | 0.026|
| High                          | 93.1                               |              |     |
| PDK1 expression               |                                    |              |     |
| Low                           | 82.3                               | 5.990        | 0.014|
| High                          | 64.3                               |              |     |
| UFM1/PDK1 expression          |                                    |              |     |
| UFM1 high and PDK1 low        | 100.0                              | 11.290       | 0.010|
| UFM1 and PDK1 high            | 84.6                               |              |     |
| UFM1 and PDK1 low             | 78.0                               |              |     |
| UFM1 low and PDK1 high        | 58.4                               |              |     |
cells [36]. Alfonso et al. have shown that PDK1-Akt signaling pathway activity is directly related to EMT, and inhibition of the PDK1-Akt signaling pathway can transform endothelial cells in the embryonic atrioventricular pathway into mesenchymal cells, which is similar to our findings [37]. In addition, we also demonstrated that UFM1 could inhibit PDK1 expression at the post-translational level. When UFM1 expression was upregulated, the level of ubiquitination of PDK1 was decreased, and the level of PDK1 protein was increased. Conversely, when UFM1 expression was decreased, the level of ubiquitination of PDK1 was increased, and the protein levels were decreased. Hak Ha et al. reported that estrogen receptor α can promote the transcriptional activation of estrogen receptor and growth of breast cancer by competitively binding to the UFM1-specific protease UfSP2 bound to the ASC1 zinc finger structure [7]. In another study, UFM1 was observed to interact with IKKβ protein and ubiquitinate-modify IKKβ, thus enhancing the transcriptional activity of NF-κB, which is involved in NF-κB signaling pathway regulation [38]. In this study, we found that (through the Gene MANIA public database) the modification system of UFM1 interacted with PDK1 (Additional file 6: Figure S4C). Furthermore, in the clinical specimens from patients, the expression of UFM1 and PDK1 had a significant effect on the prognosis of patients. Patients with low expression of UFM1 and high expression of PDK1 had the worst prognosis. Therefore, we believe that UFM1 interacts with PDK1 and undergoes ubiquitination to reduce its expression level, which in turn reduces the phosphorylation level of AKT/GSK3β, inhibiting EMT. Our findings provide a novel mechanism for the tumorigenic activity of PDK1 in epithelial-derived cancer cells.

**Conclusion**

In summary, our study shows that UFM1 may downregulate the expression level of PDK1, which inhibits the AKT/GSK3β pathway and downregulating the EMT activity of gastric cancer cells, leading to suppress the invasion and metastasis of gastric cancer cells. These findings suggest that UFM1 may be a potential new marker for the treatment of gastric cancer. The content of this study is summarized in a simplified schematic diagram (Fig. 6e).

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s13046-019-1416-4.

**Additional file 1.** Materials and Methods.

**Additional file 2: Table S1.** Primer sequence.

**Additional file 3: Figure S1.** (A) Immunohistochemical staining of UFM1 expression in gastric cancer tissue and the criteria for immunohistochemistry scores following the intensity of positive signals, magnification, × 100. (B) Oncomine data mining analysis of UFM1 levels in Wang datasets between normal tissues versus gastric cancer. (C) Kaplan-Meier curves of OS in GC patients with high or low UFM1 expression in TCGA-STAD. OS curves were generated by setting median UFM1 expression as cutoff. Analysis was performed using the UALCAN browser.

**Additional file 4: Figure S2.** (A) AGS and HGC-27 cells with stably overexpressed or knocked-down UFM1 were created. The UFM1 expression changes were confirmed by western blotting. (B) Tumor volume of the xenografts was measured every 7 days.

**Additional file 5: Figure S3.** (A) The lysates of stable AGS cells were applied to Phospho-Kinase Antibody Array, and 10 pixel densities of indicated proteins were shown. (B) PI3K inhibitor LY294002 can inhibit the invasion phenotype of AGS and HGC-27 cells; scale bar, 50 μm. (C) LY294002 significantly inhibited the phosphorylation level of AKT, but the expression level of UFM1 did not change significantly. The phosphorylation level of AKT was significantly increased after knocking down UFM1.

**Additional file 6: Figure S4.** (A) The lysates of stable AGS cells were applied to immunoprecipitation using UFM1 antibody. The immunoprecipitates were examined to blot PI3K subunits p85 and p110, AKT, EMT-related proteins E-cadherin, N-cadherin and Snail. (B) The relationship of UFM1 and PDK1 in mRNA by Linkedomics browser. There was no obvious correlation between them ($P = 0.314$). (C) UFM1 modification system could interact with PDK1 by the GeneMANIA browser. (D) AGS cells were transfected as indicated then applied to western blot. (E) PDK1 siRNA significantly reduce AGS cell invasiveness. The data are presented as the mean ± SD; scale bar, 50 μm ($^{*}P < 0.05$).

**Additional file 7: Figure S5.** (A) Immunohistochemical staining of PDK1 expression in gastric cancer tissue and the criteria for immunohistochemistry scores following the intensity of positive signals, magnification, × 100.

Table 3 Multivariate analysis of the correlation between clinicopathological parameters and survival time of patients with gastric cancer

| Covariates                                | Coefficient | Standard error | HR   | 95% CI for HR | p     |
|-------------------------------------------|-------------|----------------|------|---------------|-------|
| UFM1 expression (high vs. low)            | −1.226      | 0.735          | 0.294| 0.070–1.259   | 0.095 |
| PDK1 expression (high vs. low)            | −0.979      | 0.536          | 0.376| 0.131–1.074   | 0.068 |
| UFM1 and PDK1 expression (low/low vs. high and/or high) | 1.178      | 0.453          | 3.247| 1.336–7.891   | 0.009 |
| Depth of invasion (T3,T4 vs. T1,T2)       | 1.071       | 1.045          | 2.920| 0.376–22.635  | 0.305 |
| Lymph node metastasis (positive vs. negative) | 1.538      | 1.020          | 1.974| 0.631–34.367  | 0.132 |
| Distant metastasis (positive vs. negative) | 0.861       | 0.544          | 2.365| 0.815–6.8631  | 0.113 |
| TNM stage (stage III and IV vs. I and II) | −1.630      | 0.608          | 7.195| 0.060–64.65   | 0.007 |
Abbreviations
AJCC: American joint committee on cancer; AKT: Protein kinase B (PKB); EMT: Epithelial-mesenchymal transition; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; GSK3B: Glycogen synthase kinase 3 beta; LPS: Lipopolysaccharides; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; PCR: Polymerase Chain Reaction; PKD1: Protein 3-phosphoinositide-dependent protein kinase-1; PI3K: Phosphatidylinositol 3-kinases; TCGA: The cancer genome atlas; TNM: Tumor-node-metastasis; UFC1: Ubiquitin Fold Modifier Conjugating Enzyme 1; UFM1: Ubiquitin-fold modifier 1

Acknowledgments
The authors would like to thank the Key Laboratory of Ministry of Education of Gastrointestinal Cancer and the Key Laboratory of Tumor Microbiology, Fujian Medical University for providing experimental equipment and technical support.

Ethical approval and consent to participate
All participants provided informed written consent, and the study protocol was approved by Fujian Medical University Union Hospital Ethics Committee and Fujian Medical University Experimental Animal Center.

Authors' contributions
Conception and design: CHZ, CHH, PL. Development of methodology: JXL, XSX, XFWM, NZL. Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): SLQ, JBW, JL, QYC, LLC, ML, RHT. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): JXL, XSX, XFWM, NZL, SLQ, JBW, JL, QYC, LLC, YHY. Writing, review, and/or revision of the manuscript: JXL, XSX, XFWM, CY. Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): JXL, XSX, XFWM, SLQ, CY, JWX, JBW, JL, QYC, LLC, ML, RHT. Study supervision: CHZ, CMH, PL. All authors read and approved the final manuscript.

Funding
This study was funded by the National Natural Science Foundation of China (grant no. 81871899), the Science Foundation of the Fujian Province, China (grant no. 2018J0307), the Startup Fund for Scientific Research, Fujian Medical University (grant no. 2016QH024), the Scientific and Technological Innovation Joint Capital Projects of Fujian Province (grant no. 2016Y9031), the Minimally Invasive Medical Center of Fujian Province (grant no. 2017I0807) and the Science Foundation of Fujian Province (grant no. 2016J01463); Scientific and technological innovation joint capital projects of Fujian Province (2018Y9003).

Availability of data and materials
All data generated during this study are included in this article.

Consent for publication
Informed consent was obtained from all individual participants included in the study.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China. 2Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou 350108, Fujian Province, China. 3Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou 350108, Fujian Province, China. 4Department of Pathology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China. 5Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Received: 2 May 2019 Accepted: 9 September 2019
Published online: 18 September 2019

References
1. Karimi P, Ismail F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric Cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23:700–13.
2. Sadeh A, Cataniacci DV. Gastroesophageal cancer: focus on epidemiology, classification, and staging. Discov Med. 2013;16:103–11.
3. Jiang SH, Kim KJ, Oh MH, Lee JH, Lee HI, Cho HD, et al. Clinicopathological significance of elevated PKKCA expression in gastric Cancer. J Gastric Cancer. 2016;16:85–92.
4. Masaaki K, Tomoki C, Kanako T, Shun-ichiro I, Isei T, Noriko O, et al. A novel protein-conjugating system for UfM1, a ubiquitin-fold modifier. EMBO J. 2014;23:1977–86.
5. Patrick H, Jens D, Dirk S, Hannah V, Sareetha K, Clio G, et al. The ubiquitin-fold modifier 1 (UfM1) cascade of Caenorhabditis elegans. J Biol Chem. 2013;288:10661–71.
6. Sasakawa H, Sakata E, Yamaguchi Y, Komatsu M, Tatsumi K, Komimani E, et al. Solution structure and dynamics of UfM1, a ubiquitin-fold modifier 1. Biochem Biophys Res Commun. 2006;343:21–6.
7. Ha BH, Jeon YJ, Shin SC, Tatsumi K, Komatsu M, Tanaka K, et al. Structure of ubiquitin-fold modifier 1-specific protease USP25. J Biol Chem. 2011;286:10248.
8. Sreenivas G, Connelly PS, Daniels MP, Robert D, Poonam S, Nakhasi HL. Deletion of mitochondrial associated ubiquitin fold modifier protein UfM1 in Leishmania donovani results in loss of β-oxidation of fatty acids and blocks cell division in the amastigote stage. Mol Microbiol. 2012;86:187–98.
9. Hu X, Pang Q, Shen Q, Liu H, He J, Wang J, et al. Ubiquitin-fold modifier 1 inhibitors apoptosis by suppressing the endoplasmic reticulum stress response in RAW264.7 cells. Int J Mol Med. 2014;33:1539–46.
10. Mizushima T, Tatsumi K, Ozaki Y, Kawakami T, Suzuki A, Ogashara K, et al. Crystal structure of Ufc1, the UfM1-conjugating enzyme. Biochem Biophys Res Commun. 2007;362:1079–84.
11. Ishimura R, Obata M, Kagaeyama S, Daniel J, Tanaka K, Komatsu M. A novel approach to assess the ubiquitin-fold modifier 1-system in cells. FBEBS Lett. 2016;591:196–204.
12. Xi P, Ding D, Zhou J, Wang M, Cong YS. DDIRGK1 regulates NF-κb activity by modulating IkKβ stability. PLoS One. 2013;8:e64231.
13. Yoo HM, Kang SH, Kim JY, Lee JE, Seong MW, Lee SW, et al. Modification of ASC1 by UfM1 is crucial for Ehrlich transactivation and breast Cancer development. Mol Cell. 2014;56:261–74.
14. Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017. p. 203–20.
15. Cao L, Zhou J, Zhang J, Wu S, Yang X, Zhao X, et al. Cyclin-dependent kinase 5 decreases in gastric cancer and its nuclear accumulation suppresses gastric tumorigenesis. Clin Cancer Res. 2015;21:1419.
16. Kannan J, Lxox TDS. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25:402–8.
17. Wang JH, Wang ZW, Yun L, Huang CQ, Zheng CH, Ping L, et al. CDK5RAP3 acts as a tumor suppressor in gastric cancer through inhibition of β-catenin signaling. Cancer Lett. 2016;365:171–8.
18. Chandrashekar DS, Bashel B, Babuubramamiya SAH, Creighton CJ, Ponce-Rodriguez J, Chakravathi B, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:469–58.
19. Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multiomics data within and across 32 cancer types. Nucleic Acids Res. 2018;46:<D63.14.309–118.
20. Wang JH, Wang ZW, Yun L, Huang CQ, Zheng CH, Ping L, et al. CDK5RAP3 acts as a tumor suppressor in gastric cancer through inhibition of β-catenin signaling. Cancer Lett. 2016;365:171–8.
21. Chandrashekar DS, Bashel B, Babuubramamiya SAH, Creighton CJ, Ponce-Rodriguez J, Chakravathi B, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:469–58.
22. Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multiomics data within and across 32 cancer types. Nucleic Acids Res. 2018;46:<D63.14.309–118.
23. Wang JH, Wang ZW, Yun L, Huang CQ, Zheng CH, Ping L, et al. CDK5RAP3 acts as a tumor suppressor in gastric cancer through inhibition of β-catenin signaling. Cancer Lett. 2016;365:171–8.
24. Chandrashekar DS, Bashel B, Babuubramamiya SAH, Creighton CJ, Ponce-Rodriguez J, Chakravathi B, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:469–58.
25. Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multiomics data within and across 32 cancer types. Nucleic Acids Res. 2018;46:<D63.14.309–118.
25. Samy, L., Jian, X., Rik, D. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.
26. Ulrich, V., Jonathon, C., Yukari, O., Lindsay, A., Mitsuyasu, K., Sylvie, T., et al. Analysis of epithelial-mesenchymal transition induced by transforming growth factor β. Methods Mol Biol. 2016;1344:147–81.
27. Saunders, LR, Mclay, DR. Sub-circuits of a gene regulatory network control a developmental epithelial-mesenchymal transition. Development. 2014;141:1503–13.
28. Biondi, RM. Phosphoinositide-dependent protein kinase 1, a sensor of protein conformation. Trends Biochem Sci. 2004;29:136–42.
29. Li, DC, Li, W, Zhou, QX, Lu, J, Peng, YL. Molecular cloning and characterization of a putative protein kinase gene from the thermophilic fungus Thermomyces lanuginosus. DNA Seq. 2007;18:423–33.
30. Bayascas, JR. PDK1: the major transducer of PI 3-kinase actions. Curr Top Microbiol Immunol. 2010;346:9–29.
31. Gagliardi, PA, Blasio, LD, Primo, L. PDK1: a signalling hub for cell migration and tumor invasion. Biochim Biophys Acta. 2015;1856:178–88.
32. Mora, A, Komander, D, Aalten, DMFV, Alessi, DR. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol. 2004;15:161–70.
33. Li, W, Song, R, Fang, X, Wang, L, Chen, W, Tang, P, Yu, B, et al. SBF-1, a synthetic steroidal glycoside, inhibits melanoma growth and metastasis through blocking interaction between PDK1 and AKT3. Biochem Pharmacol. 2012;84:172–81.
34. Chan, TH, Qamra, A, Tan, KT, Guo, J, Yang, H, Qi, L, et al. ADAR-mediated RNA editing predicts progression and prognosis of gastric Cancer. Gastroenterology. 2016;151:637–50 e10.
35. Deng, YZ, Yao, F, Li, JJ, Mao, ZF, Hu, PT, Long, LY, et al. RACK1 suppresses gastric tumorigenesis by stabilizing the β-catenin destruction complex. Gastroenterology. 2012;142:812–23.e15.
36. Fujisawa, S, Kawano, Y, Yuki, H, Okuno, Y, Nosaka, K, Mitsuya, H, et al. PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br J Cancer. 2013;108:170–8.
37. Qiuting, F, Ruomin, D, Fang, T, Zai, C, Shuangshuang, L, Wenjing, F, et al. PDK1 regulates vascular remodeling and promotes epithelial-mesenchymal transition in cardiac development. Mol Cell Biol. 2010;30:3711–21.
38. Li, Z, He, Z, Kong, Y, et al. Ufm1 inhibits LPS-induced endothelial cell inflammatory responses through the NF-κB signaling pathway. Int J Mol Med. 2017;39:1119–26.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.